Vaccines for the Twenty-First Century

  • R. B. Belshe
Conference paper


Recent dramatic progress in molecular biology is being translated into improved or new vaccines to prevent infectious diseases. The ability to clone genetic material, to manipulate it to express high quality, purified antigens and to make recombinant vectors is leading to a new generation of safe and effective vaccines. The introduction of these new vaccines will be an ongoing process involving multiple manufacturers of vaccines from many countries. The purpose of this chapter is to summarize the types of vaccines and technologies that are likely to emerge as significant advances in vaccinology as we approach the twenty-first century.


Respiratory Syncytial Virus Conjugate Vaccine Pneumococcal Conjugate Vaccine Oral Poliovirus Vaccine Technol Assess Health 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    ACP Task Force on Adult Immunization and Infectious Diseases Society of America (1994) Guide for adult Immunization, 3rd edn. American College of Physicians, 1994Google Scholar
  2. 2.
    Stein KE (1994) Glycoconjugate vaccines. The promise of new technologies. Int J Technol Assess Health Care 10(1): 167–176PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson EL, Decker MD, Englund JA, Edwards KM, Anderson P, Mclnnes P, Belshe RB (1995) Interchangeability of conjugated Haemophilus influenzae type b vaccines in Infants. JAMA 273:849–853PubMedCrossRefGoogle Scholar
  4. 4.
    Anderson EL, Kennedy DJ, Geldmacher KM, Donnelly, J, Mendelman PM (1996) Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 128:649–653PubMedCrossRefGoogle Scholar
  5. 5.
    Belshe RB, Karron RA, Newman FK, Anderson EL, Nugent SL, Steinhoff M, Clements ML, Wilson MH, Hall SL, Tierney EL, Murphy BR (1992) Evaluation of a live attenuated, cold-adapted parainfluenzae virus type 3 vaccine in children. J Clin Microbiol 30:2064–2070PubMedGoogle Scholar
  6. 6.
    Belshe RB, Swierkosz, EM, Anderson EL, Newman FK, Nugent SL, Maassab J (1992) Immunization of infants and young children with live attenuated trivalent cold recombinant influenza A H1N1, H3N2, and B vaccine. J Infect Dis 165:727–732PubMedCrossRefGoogle Scholar
  7. 7.
    La Montagne JR, Rabinovich NR (1994) The promise of new technologies. Int J Technol Assess Health Care 10(1): 7–13PubMedCrossRefGoogle Scholar
  8. 8.
    Mekalanos JJ (1994) Live attenuated vaccine vectors. The promise of new technologies. Int J Technol Assess Health Care 10(1): 131–142PubMedCrossRefGoogle Scholar
  9. 9.
    Gray BM, Converse GM, Dillon HC (1980) Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage and infection during the first 24 months of life. J Infect Dis 142:923–933PubMedCrossRefGoogle Scholar
  10. 10.
    Ellis RW, Douglas RG Jr (1994) Combination vaccines. The promise of new technologies. Int J Technol Assess Health Care 10(1): 185–192PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • R. B. Belshe

There are no affiliations available

Personalised recommendations